APIMEDS PHARMACEUTICALS US, INC. Accounts Payable and Accrued Liabilities
APIMEDS PHARMACEUTICALS US, INC. (APUS) had Accounts Payable and Accrued Liabilities of $2.98 million as of 2026-03-31, per its 10-Q filed 2026-05-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2026-05-26
- 2026-03-31: Accounts Payable and Accrued Liabilities $2.98M.
- 2025-12-31: Accounts Payable and Accrued Liabilities $918.65K.
- 2025-09-30: Accounts Payable and Accrued Liabilities $567.63K.
- 2025-06-30: Accounts Payable and Accrued Liabilities $119.14K.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2026-03-31 | $2.98M 10-Q · filed 2026-05-26 |
| 2025-12-31 | $918.65K 10-Q · filed 2026-05-26 |
| 2025-09-30 | $567.63K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $119.14K 10-Q · filed 2025-08-19 |
| 2025-03-31 | $935.20K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $591.19K 10-Q · filed 2025-11-12 |
| 2023-12-31 | $54.44K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |